Medicaid

Columbia Pacific CCO – Notice of Data Event

PORTLAND, Ore., Dec. 26, 2025 /PRNewswire/ -- On or about October 27, 2025, Columbia Pacific CCO learned that one or more people…

2 weeks ago

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert…

3 weeks ago

2026 Payer IT Outsourcing Outlook: Outcome-Based Managed Services, Production-Grade GenAI Governance, and Vendor-Risk Enforcement

Black Book Research Q4 flash survey shows health plans shifting from effort-based sourcing to KPI-backed operating models, tightening third- and…

3 weeks ago

Best Peptides for Muscle Growth: Prescription Sermorelin Access, Injectable vs. Dissolving Tablets, and Realistic Expectations

Platform Analysis: Injectable vs. Dissolving Tablet Formats, Prescription Requirements, Monthly Subscription Costs, and Timeline Expectations for Growth Hormone Secretagogue TherapyAUSTIN,…

3 weeks ago

Organogenesis Announces Initiation of Biologics License Application for ReNu®

Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026CANTON, Mass., Dec. 23,…

3 weeks ago

Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage

Centennial, Colorado--(Newsfile Corp. - December 24, 2025) - The Obesity Medicine Association (OMA) released its Position Statement on Medicare and…

3 weeks ago

Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test

CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total…

3 weeks ago

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on…

3 weeks ago

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved…

3 weeks ago

CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD

SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our",…

3 weeks ago